Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Large Growth in Short Interest

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a large growth in short interest in the month of March. As of March 13th, there was short interest totaling 56,970 shares, a growth of 53.3% from the February 26th total of 37,152 shares. Approximately 5.9% of the company’s shares are short sold. Based on an average daily trading volume, of 276,289 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics as of its most recent SEC filing. 18.47% of the stock is currently owned by hedge funds and other institutional investors.

Bluejay Diagnostics Stock Performance

Bluejay Diagnostics stock opened at $1.96 on Friday. Bluejay Diagnostics has a 52-week low of $1.70 and a 52-week high of $40.80. The stock has a market capitalization of $1.90 million, a price-to-earnings ratio of 0.00 and a beta of 0.72. The stock’s 50 day moving average price is $2.47 and its two-hundred day moving average price is $4.73.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its earnings results on Friday, March 6th. The company reported $3.23 earnings per share for the quarter.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.